Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – ...
Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
Hypertension commonly co-exists with obstructive sleep apnea (OSA). However, the role of renin-angiotensin-aldosterone system (RAAS) in the development of hypertension in OSA patients remains poorly ...
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, University Health, ...
Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
Introduction: As one of the most common complications of diabetes, diabetic cardiomyopathy (DCM) is the main cause of heart failure in patients with diabetes. However, the lack of effective treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback